Owner-Operator Independent Drivers Assc

SECRETARY OF THE SENATE
04 JAN 30 AM 9: 10

SECRETARY OF THE SE
04 JAN 30 AM 9:

National Headquarters: OOIDA Building • I-70 at
1 NW OOIDA Drive • PO Box 1000 • Grand Vall
Tel: (816) 229-5791 • Fa
e-mail: ooida@ooida.com • web site

January 23, 2004

Office of the Clerk
U.S. House of Representatives
Washington, D.C. 20515-6601

Re: SAME – ID: 35211000

Dear Sir or Madame,

I received the First Notice of Non-Receipt regarding the Lobbying Report for the period July 1, 2002 to December 31, 2002. That report was executed and mailed via the postal service on 1/21/03. I have enclosed the copy that I kept in our files. I can only assume that the original was lost in the mail.

Thank you for your attention to this matter.

Sincerely,

Angel Burnell

Angel Burnell
Executive Assistant

/amb
Enclosure



EMORD & ASSOCIATES P.C.

BURKE PROFESSIONAL CENTER
5282 LYNGATE COURT
BURKE, VIRGINIA 22015

1050 SEVENTEENTH STREET, N.W.
SUITE 600
WASHINGTON, D.C. 20036

PHONE: (202) 466-6937 • FAX: (202) 466-6938
WEB SITE: www.emord.com
E-MAIL: aferrenz@emord.com

SECRETARY OF T
04 JAN 30 AM

January 26, 2004

VIA UPS GROUND
Clerk of the House of Representatives
Legislative Resource Center
B-106
Washington DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington DC 20510

To Whom It May Concern:

Please find enclosed (1) the 2003 Year End Lobbying Report for Emord & Associate ("Emord's") representation of Jerome Stevens Pharmaceuticals, Inc. (House # 341704010); (2) the 2002 Year End Lobbying Report for Emord's representation of Jerome Stevens Pharmaceuticals, Inc.

The above 2002 Year End report is in response to your January 13, 2004 Notice of N receipt in which a written explanation is requested. We first filed a lobbying report for Jero Stevens on November 12, 2002. Our records do not reflect having received a green notice o report due card for the end of year 2002 report. It is likely that because our initial filing was close to the end of the 2002 year that Jerome Stevens was not a part of those Year End notic that were mailed out in January 2003. We apologize for any oversight.

Please do not hesitate to contact us if you have any questions regarding the attached reports.

Sincerely,

Jonathan W. Emord
Andrea G. Ferrenz

Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS
04 JAN 30 PM 1:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required to Complete This Page**

1. Registrant Name

Emord & Associates P.C.

2. Address ☐ Check if different than previously reported

5282 Lyngate Court

3. Principal Place of Business (if different from line 2)

Burke — City:

VA/22015 — State/zip (or Country)

4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Andrea G. Ferrenz	(202) 466-6937	aferrenz@emord.com	

7. Client Name ☐ Self

Jerome Stevens Pharmaceuticals, Inc.

6. House ID # 34174010

TYPE OF REPORT

8. Year 2002 Midyear (January 1-June 30) ☐ **OR** Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ➪ Termination Date _____ 11. No Lobbyin

INCOME OR EXPENSES - Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☑

$10,000 or more ☐ ➪ $ _____
Income (nearest $20,000)

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this repor period were:

Less than $10,000 ☐

$10,000 or more ☐ ➪ $ _____
Expenses (nearest $20,000

14. REPORTING METHOD. Check box to indicate ex accounting method. See instructions for description of o

☐ **Method A.** Reporting amounts using LDA definiti

☐ **Method B.** Reporting amounts under section 6033 Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(Internal Revenue Code

Signature _____ Date _____

Printed Name and Title Jonathan W. Emord, President

LD-2 (REV. 4/03) PAGE 1 o

Registrant Name Emord & Associates P.C. Client Name Jerome Stevens Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific lobbying issues

The Food and Drug Administration's regulation of orally administered levothyroxine sodium drugs

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Jonathan W. Emord	
Andrea G. Ferrenz	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☑ Check if None

Signature [signature] Date 1-26-04

Printed Name and Title Jonathan W. Emord, President